<DOC>
	<DOCNO>NCT01041573</DOCNO>
	<brief_summary>The primary objective ass systemic local safety profile purify inactivated Japanese Encephalitis Virus ( JEV ) vaccine IC51 administer two dos 28 day interval Month 7 first IC51 vaccination pediatric population endemic region .</brief_summary>
	<brief_title>Safety Immunogenicity Japanese Encephalitis Vaccine IC51 ( IXIARO® ) Pediatric Population</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female healthy child adolescent age &gt; 2 month &lt; 18 year time first vaccination . Written inform consent subject 's legal representative ( ) , accord local requirement , write informed assent subject , applicable . Female subject : either childbearing potential negative pregnancy test , female menarche willingness practice reliable method contraception . Clinical manifestation Japanese Encephalitis History Flavivirus vaccination ( include investigational vaccine ) History vaccination HAVRIX®720 and/or Prevnar® History immunodeficiency immunosuppressive therapy Known HIV , HBV HCV infection History hypersensitivity reaction vaccine Acute febrile infection visit subject receive vaccination Active passive immunization within 2 week prior first IC51 vaccination second IC51 vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Japanese Encephalitis Vaccine</keyword>
	<keyword>endemic country</keyword>
	<keyword>assess systemic local safety profile purify inactivated Japanese Encephalitis Virus ( JEV ) vaccine IC51</keyword>
</DOC>